Off-label prescribing refers to prescribing a Therapeutic Goods Administration (TGA)–approved medicine for an indication, dose, route of administration or patient group that is not listed in the approved product information. It also includes modification of the dosage form outside of the preparation directions provided in the product information (e.g. crushing or dividing tablets that are not intended to be crushed or divided, or using the medicine for extemporaneous compounding).1

Off-label prescribing is a common and sometimes necessary practice. Prescribers (medical and non-medical) need to be aware of the clinical, safety, ethical and legal issues associated with off-label prescribing.2,3

The Council of Australian Therapeutic Advisory Groups (CATAG) has updated its guidance for the off-label use of medicines, supported by funding from the Australian Commission on Safety and Quality in Heath Care.1 A key change is that the scope has been expanded to include primary care in addition to hospitals.

There are 8 guiding principles that provide a practical framework for decision-making about off-label prescribing based on the strength of available evidence, clinical circumstances and patient preference.1 The principles emphasise:

  • using a medicine off label only when other options are unavailable, less suitable, ineffective or not tolerated
  • using the highest quality and most clinically relevant evidence available to guide prescribing decisions
  • seeking expert advice when considering off-label use that is outside routine or standard care
  • consumer involvement through shared decision-making with informed consent, especially for non-routine use of a medicine or where evidence is limited
  • appropriate documentation and monitoring of off-label medicine use
  • communication of off-label use at transitions of care
  • evaluation of outcomes and, where appropriate, dissemination of findings to add to the evidence base
  • consideration of legal and professional responsibilities.

The Australian Health Practitioner Regulation Agency (AHPRA) has also recently published a brief guidance for off-label prescribing (and prescribing of unapproved medicines).3 The AHPRA guidance emphasises that prescribers should ensure they have the necessary knowledge, skills and training to provide safe care when prescribing off-label or unapproved medicines, and comply with relevant jurisdictional and national legislative and regulatory requirements. It notes that the National Prescribing Competencies Framework includes a competency on off-label prescribing that covers:3

  • establishing therapeutic need
  • shared decision-making and informed consent
  • documenting the reason for use in the patient’s health record.

The AHPRA guidance also discusses managing conflicts of interest, ensuring continuity of care and reporting adverse drug reactions to the TGA.3

The CATAG has produced a consumer counselling tool that supports healthcare professionals when discussing off-label use of a medicine with patients and carers and facilitates shared decision-making and informed consent.4 While the consumer tool has been designed for hospitals, it may be useful in other settings.

Together these guides and tools can help clinicians to optimise quality and safety of patient care when prescribing off-label medications.

 

Australian Prescriber welcomes Feedback.